| Paris | |
| 0 | |
| Discovers and develops global health solutions from prevention to treatment against cardiometabolic diseases | |
| For its solution to prevent Type 2 Diabetes, VALBIOTIS finished its preclinical studies at the end of 2015 with spectacular results. VALBIOTIS will begin in January 2016 a safety study and in March 2016 a double-blind, randomized, multicenter controlled study in 80 abdominally obese patients with combined dyslipidemia and prediabetes. VALBIOTIS will continue in 2016 is preclinical studies to develop a new drug to treat type 2 diabetes and its complication |
|
| PELTIER Sébastien | |
| www.valbiotis.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 13 fois.